This speculative ASX stock could almost double in value

Bell Potter thinks investors could almost double their money with this high risk option.

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Every investor has a different risk appetite. Some investors play it safe and buy low risk, defensive ASX stocks. Others are willing to risk a little for stronger potential returns. And a handful will seek the huge potential returns on offer from the speculative side of the market.

If you're in the latter category, then it could be worth checking out the speculative ASX stock in this article.

That's because the team at Bell Potter believes that it has the potential to almost double in value from current levels.

Which speculative ASX stock?

The company in question is Immutep Ltd (ASX: IMM). It is a $520 million, clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) immunotherapy for cancer and autoimmune disease.

Immutep's eftilagimod alfa (efti) product is its proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer.

Management notes that as a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes.

It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system's ability to fight cancer.

What is the broker saying?

Bell Potter highlights that the speculative ASX stock is on the cusp of becoming a phase three company with a significant market opportunity. It notes:

At the end of CY24, IMM will transition into a Phase 3 company targeting one of the most lucrative oncology indications, first-line (1L) non-small cell lung cancer (NSCLC).

IMM will target all patients regardless of PD-L1 expression and test the regimen of Efti + pembrolizumab + chemo in ~750 patients. This is a positive choice in our view as it broadens the TAM to ~70k US patients diagnosed annually (or ~US$11b) and aims to improve upon the best standard of care currently available to patients, thereby speeding up Phase 3 recruitment and real-world adoption. Recruitment will start end-CY24/early-CY25.

The broker was also pleased to see that Immutep has successfully raised $100 million from investors recently. It believes this "improved balance sheet provides ~2.5 years of runway to end-CY26 (post Phase 3 futility analysis) and clears any perceived funding overhang in the near-term ahead of key readouts in HNSCC and beyond."

Big potential returns

Bell Potter has responded to the above by reaffirming its speculative buy rating and 80 cents price target on the ASX stock.

Based on its current share price of 41%, this implies potential upside of 95% for investors over the next 12 months. It concludes:

With longer-term value being driven by the 1L NSCLC Phase 3, short-term attention now shifts to the imminent release of Phase 2b data by 30th June in head & neck cancer, where Efti + Keytruda is being evaluated head-to-head against Keytruda.

We maintain our BUY (speculative) recommendation and $0.80/share valuation. We remain positive ahead of the significant Ph2b readout due in the next ~2 weeks.

Should you invest $1,000 in 4ds Memory Limited right now?

Before you buy 4ds Memory Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and 4ds Memory Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Five retirees do a conga line dance on the beach celebrating the special dividend announced by Grange Resources today
Broker Notes

Why Macquarie thinks the NZ retirement village sector could be an emerging opportunity for ASX investors

Oceania Healthcare and Summerset could quietly emerge as high-upside plays for patient ASX investors.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

5 high-conviction ASX 200 shares to buy

Brokers are tipping these shares as buys. Here’s what they rate highly.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Happy woman working on a laptop.
Broker Notes

Macquarie's best ASX 200 share picks in each of the 11 market sectors

Looking for stock-buying opportunities?

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Two brokers analysing stocks.
Technology Shares

What are top brokers saying about Xero shares?

Is now the time to buy this popular share? Let's see what brokers are saying.

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format.
Broker Notes

8 alternative ASX financial shares to buy instead of bank stocks: broker

Top broker Macquarie has put an outperform rating on scores of non-bank ASX financial shares.

Read more »

A man in suit and tie is smug about his suitcase bursting with cash.
Broker Notes

These ASX 200 shares could rise 25% to 35%

Analysts expect these shares to deliver big returns over the next 12 months.

Read more »